Trending News
News
News
Nanohale Acquires R&D and Service Units of Scil Technology GmbH
Transaction creates new Nanohale subsidiary named Formycon GmbH.
News
Idera Pharmaceuticals Announces Selection of Toll-like Receptor (TLR) Agonist Candidates for Evaluation as Vaccine Adjuvants by Merck
The partners announced the selection of several novel agonists targeted to TLR7, TLR8 or TLR9 for evaluation and use as vaccine adjuvant candidates under the companies' collaboration and license agreement.
News
Presidio Pharmaceuticals Reports Progress with Hepatitis C Antiviral Programs
Completion of Phase 1a dose-ranging assessment of PPI-668, a potent, pan-genotypic second-generation hepatitis C virus (HCV) NS5A inhibitor, in healthy volunteers and subsequent advancement to a Phase 1b assessment of the dose-related efficacy in hepatitis C patients.
News
NovaBay Pharmaceuticals Announces Strategic Marketing Agreement for NeutroPhase in China
The commercial partnership with Pioneer Pharma Co., Ltd., a Shanghai-based company that markets high-end pharmaceutical products into China, is for the commercialization of NeutroPhase in this territory. Under the terms of the agreement, NovaBay will receive an upfront payment of over $300,000.
News
Sigma-Aldrich to Acquire BioReliance
Sigma-Aldrich Corporation has signed an agreement to acquire BioReliance Holdings, Inc. from Avista Capital Partners for $350 million in cash.
News
Thallion and LFB Complete Patient Enrollment of Phase II SHIGATEC Trial
The companies announced that they have completed patient enrollment for the high dose cohort (3 mg/kg) of the Phase II SHIGATEC trial, evaluating Shigamabs® as a treatment for Shiga toxin-producing E. coli (STEC) infection.
News
Kadmon Acquires First-in-Class Ras Antagonist from Concordia Pharmaceuticals
The companies announced the signing of an asset purchase agreement under which Kadmon has acquired all rights to salirasib, a Phase 2, novel, orally available, small molecule therapeutic in development for the treatment of solid tumors.
News
KAI Pharmaceuticals Announces Initiation of Second Phase 2 Study of KAI-4169
The novel pharmaceutical agent is being tested for the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) in hemodialysis patients with secondary hyperparathyroidism (SHPT).
News
Endo Pharmaceuticals and BioDelivery Sciences International Sign Licensing Agreement
The agreement is to license for BEMA Buprenorphine, a transmucosal form of buprenorphine, a partial mu-opiate receptor agonist.
News
Cystinosis Research Foundation Awards $2 Million to Find Cure for Deadly, Genetic Disease
The research foundation issued five grants totaling $776,693 to cystinosis researchers worldwide investigating better treatments and a cure for the disease in its second round of proposals in 2011.
Advertisement